Diagnostic HYBRIDS, Inc.

Diagnostic HYBRIDS, Inc. innovates, develops, manufactures, and markets cellular and molecular diagnostic kits for various applications in detecting a range of respiratory diseases, herpes infections, thyroid function, and other markers of disease. It also develops and commercializes cell-based detection products for the pharmaceutical and biotechnology industry with a focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company offers an assortment of products that meet the needs for specimen collection, transport, multi-virus cell culture amplification, and sensitive and specific virus detection using monoclonal antibody kits and reagents. It supports educational programs for Influenza A, Influenza B, RSV, MPV, Adenovirus, and Parainfluenza 1, 2, and 3 through direct speaker programs and educational grants, as well as Internet-based education programs. The company also provides products and services for non-diagnostic applications including, in vitro toxicology and metabolism products and services, such as primary hepatocytes and hepatocyte-based assays. It offers respiratory, herpes, chlamydia, enterovirus, cell, C. Difficile Toxin, Flocked Swabs and UTM, and media and supplement product families. Diagnostic HYBRIDS, Inc. was founded in 1983 and is headquartered in Athens, Ohio.